University of Minnesota. Driven to Discover.
Activity resurges in Beni, the outbreak's former epicenter.
The $170.2 million in BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of two Ebola drugs.
Though global risk remains low, 7 countries have begun screening at airports and ports of entry.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.